V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10008663 | 10007756 | 1.66 | 86.65 | Palliative (P) | 2017-09-18 | 2017-09-18 | NIVOLUMAB | 02 | null | 10483915 | FLUOROURACIL + MITOMYCIN + RT |
| 10008664 | 10005565 | 1.7 | 87.75 | Palliative (P) | 2017-01-28 | 2017-03-28 | CAPECITABINE + RT | N | Y | 10489253 | MPV |
| 10008665 | 10005567 | 1.79 | 80 | Palliative (P) | 2016-09-18 | 2016-10-18 | Cyclophosphamide oral | N | N | 10489910 | CISPLATIN + RT |
| 10008666 | 10005568 | 1.71 | 66 | Palliative (P) | 2018-03-13 | 2018-03-13 | Bortezomib +/- Dexamethasone | 02 | N | 10490897 | GEMCITABINE + NAB-PACLITAXEL |
| 10008667 | 10005570 | 1.58 | 70.6 | Palliative (P) | null | 2016-06-22 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | null | 10491733 | FEC |
| 10008668 | 10005574 | 1.73 | 89 | Palliative (P) | 2018-11-25 | 2019-03-15 | Melphalan IV High dose | 2 | N | 10505211 | CABAZITAXEL |
| 10008669 | 10005578 | 1.67 | 91 | Palliative (P) | 2017-11-20 | 2017-11-29 | CETUXIMAB | N | N | 10506839 | CYCLOPHOSPHAMIDE |
| 10008670 | 10005580 | 1.59 | 62.9 | Adjuvant (A) | null | 2018-07-23 | Bendamustine + Obinutuzumab | 2 | N | 10510766 | ERIBULIN |
| 10008671 | 10005582 | 1.76 | 71 | Palliative (P) | 2018-03-31 | 2018-04-18 | Capecitabine (21days) + Carboplatin | 02 | N | 10511472 | VISMODEGIB |
| 10008672 | 10005583 | 1.76 | null | null | 2018-03-14 | 2019-01-20 | PIXANTRONE | N | N | 10512326 | R-EPOCH |
| 10008673 | 10005587 | null | 75.8 | Disease modification (D) | 2019-04-24 | 2019-04-24 | VEDex | N | N | 10514736 | CISPLATIN + FLUOROURACIL |
| 10008674 | 10005589 | 1.64 | 90.3 | Neo-adjuvant (N) | 2017-06-12 | 2017-07-11 | CHLORAMBUCIL + OBINUTUZUMAB | 2 | N | 10517788 | ENZALUTAMIDE |
| 10008675 | 10007767 | 1.81 | 111 | Adjuvant (A) | 2016-06-19 | 2016-07-03 | Venetoclax | 02 | N | 10519332 | CYTARABINE + IDARUBICIN |
| 10008676 | 10007768 | null | 66.9 | Curative (C) | 2014-12-15 | 2016-02-06 | CISPLATIN + FLUOROURACIL | N | null | 10522479 | FLAG + IDARUBICIN |
| 10008677 | 10005593 | 1.72 | null | Palliative (P) | 2019-04-24 | 2019-04-30 | Cisplatin + Pemetrexed | N | N | 10523571 | CETUXIMAB |
| 10008678 | 10005594 | 1.87 | 75.4 | Adjuvant (A) | 2019-05-08 | 2019-05-20 | RIALTO TRIAL | N | N | 10523571 | OXALIPLATIN + MDG + PANITUMUMAB |
| 10008679 | 10005596 | 1.6 | 60 | Disease modification (D) | 2017-05-05 | 2017-05-19 | Bortezomib +/- Dexamethasone | N | null | 10526979 | LIPOSOMAL DOXORUBICIN |
| 10008680 | 10005597 | 1.86 | null | Palliative (P) | 2018-11-04 | 2018-11-04 | CISPLATIN + FLUOROURACIL | N | N | 10529619 | ENZALUTAMIDE |
| 10008681 | 10005598 | null | 68 | Palliative (P) | 2016-12-04 | 2017-01-01 | Cisplatin + Vinorelbine (PO) | N | N | 10531776 | LEAM |
| 10008682 | 10007775 | 0 | 69.4 | Palliative (P) | 2018-01-09 | 2018-02-04 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | 10540818 | VINFLUNINE |
| 10008683 | 10009294 | 1.65 | 79.3 | Curative (C) | 2019-01-06 | 2019-01-06 | VDT-PACE | 2 | N | 10542103 | CISPLATIN + DOXORUBICIN |
| 10008684 | 10005602 | 1.6 | null | Curative (C) | 2018-07-05 | 2018-07-18 | POMALIDOMIDE | null | null | 10543270 | PROCAID TRIAL |
| 10008685 | 10005605 | null | 63.8 | null | 2017-01-10 | 2017-01-10 | Cisplatin + Vinorelbine (PO) | 02 | Y | 10545578 | CHLORAMBUCIL + RITUXIMAB |
| 10008686 | 10005609 | 1.72 | 93 | Palliative (P) | 2018-07-03 | 2019-03-14 | DHAP | 02 | N | 10547434 | VEDEX |
| 10008687 | 10005610 | 0 | null | Curative (C) | 2016-10-30 | 2016-10-30 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | Y | null | 10547653 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 10008688 | 10005614 | 1.62 | 63.5 | Palliative (P) | 2017-11-13 | 2017-11-14 | Capecitabine + Cisplatin + RT | N | N | 10550481 | IMATINIB |
| 10008689 | 10005619 | 1.68 | 67.35 | Curative (C) | 2017-08-01 | 2017-12-26 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 10562316 | METHOTREXATE INTRATHECAL |
| 10008690 | 10005621 | 1.77 | 81 | Adjuvant (A) | 2018-06-29 | 2018-11-26 | Erlotinib | 01 | N | 10205908 | PMITCEBO |
| 10008691 | 10005623 | 1.76 | 110.15 | Palliative (P) | 2019-07-01 | 2019-07-05 | Carboplatin + Docetaxel | null | N | 10233873 | BENDAMUSTINE + OBINUTUZUMAB |
| 10008692 | 10005627 | 1.85 | 95.1 | Palliative (P) | 2020-05-04 | 2020-05-04 | NIVOLUMAB | N | N | 10300441 | BEVACIZUMAB + CAPECITABINE |
| 10008693 | 10005630 | 1.68 | 82 | Disease modification (D) | 2018-09-09 | 2018-09-17 | CERITINIB | N | Y | 10330739 | OSIMERTINIB |
| 10008694 | 10005633 | null | 83 | Disease modification (D) | null | 2019-06-12 | Methotrexate intrathecal | 02 | N | 10349419 | CISPLATIN + PEMETREXED |
| 10008695 | 10005635 | 1.75 | 78.1 | Palliative (P) | 2017-09-28 | 2017-09-28 | Brentuximab | 2 | N | 10350333 | BORTEZOMIB + PANOBINOSTAT |
| 10008696 | 10005646 | 1.67 | 65.8 | Palliative (P) | 2016-04-20 | 2016-07-21 | RIALTO TRIAL | N | N | 10530156 | MITOMYCIN INTRAVESICULAR |
| 10008697 | 10003531 | null | null | Adjuvant (A) | 2014-07-03 | 2015-07-22 | Rituximab (SUBCUTANEOUS Maintenance) | 02 | null | 10126144 | RITUXIMAB |
| 10008698 | 10003542 | 1.59 | 79 | Palliative (P) | 2015-09-01 | 2015-11-10 | Trastuzumab Subcutaneous | N | N | 10406386 | TRASTUZUMAB |
| 10008699 | 10003545 | 1.8 | 89 | Palliative (P) | 2015-08-04 | 2015-08-07 | Docetaxel | 02 | N | 10483135 | DOCETAXEL |
| 10008700 | 10003549 | 1.82 | 77.4 | Disease modification (D) | 2020-03-15 | 2020-03-16 | Irinotecan + Modified De Gramont | N | N | 10064622 | IRINOTECAN + MDG |
| 10008701 | 10003559 | 1.61 | null | Palliative (P) | 2016-12-10 | 2017-09-12 | PEMBROLIZUMAB | N | N | 10230548 | PEMBROLIZUMAB |
| 10008702 | 10003568 | 1.63 | 80 | Disease modification (D) | null | 2015-06-02 | Oxaliplatin + Modified de Gramont | 02 | N | 10235097 | OXALIPLATIN + MDG |
| 10008703 | 10003576 | 1.65 | 79.5 | Adjuvant (A) | 2017-07-18 | 2017-08-10 | CAPECITABINE + OXALIPLATIN | N | N | 10241016 | CAPECITABINE + OXALIPLATIN |
| 10008704 | 10003578 | null | 82 | Disease modification (D) | 2019-05-29 | 2019-06-04 | Rituximab | 2 | N | 10242036 | RITUXIMAB |
| 10008705 | 10006941 | 1.85 | null | Curative (C) | 2018-10-26 | 2018-10-26 | PEMBROLIZUMAB | 01 | N | 10244758 | PEMBROLIZUMAB |
| 10008706 | 10003591 | 1.62 | 52 | Adjuvant (A) | 2016-05-31 | 2016-06-03 | FLUOROURACIL + OXALIPLATIN | N | N | 10245829 | OXALIPLATIN + MDG |
| 10008707 | 10003596 | 1.79 | 64 | Palliative (P) | 2018-02-23 | 2018-04-06 | Paclitaxel 7 day | 02 | N | 10247058 | PACLITAXEL |
| 10008708 | 10003604 | 1.72 | 78 | Neo-adjuvant (N) | 2016-05-16 | 2016-05-17 | Trastuzumab Subcutaneous | N | N | 10250247 | TRASTUZUMAB |
| 10008709 | 10003610 | 1.79 | null | Palliative (P) | 2018-09-04 | 2018-11-27 | Rituximab | 02 | N | 10254770 | RITUXIMAB |
| 10008710 | 10003627 | 1.78 | 71.3 | Palliative (P) | 2017-11-17 | 2018-01-27 | PEMBROLIZUMAB | 2 | N | 10267419 | PEMBROLIZUMAB |
| 10008711 | 10006963 | 1.72 | 89.2 | Palliative (P) | 2017-09-14 | 2017-09-21 | Docetaxel 75mg/m2 (21 day) | N | N | 10268081 | DOCETAXEL |
| 10008712 | 10003643 | 0 | 70.1 | Palliative (P) | 2016-06-11 | 2016-06-11 | Oxaliplatin + Modified de Gramont | null | null | 10276753 | OXALIPLATIN + MDG |